Propylnorapomorphine

Propylnorapomorphine

Propylnorapomorphine
Systematic (IUPAC) name
(6aS)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Clinical data
Legal status
  • Uncontrolled
Routes of
administration
Oral
Identifiers
CAS Registry Number
ATC code None
PubChem CID:
ChemSpider
Chemical data
Formula C19H21NO2
Molecular mass 295.38 g/mol

N-n-Propylnorapomorphine (NPA) is an aporphine derivative dopamine agonist closely related to apomorphine.[1][2] In rodents it has been shown to produce hyperactivity, stereotypy, hypothermia, antinociception, and penile erection, among other effects.[3][4][5][6] Notably, its effects on locomotion are biphasic, with low doses producing inhibition and catalepsy and high doses resulting in enhancement of activity.[7] This is likely due to preferential activation of D2/D3 autoreceptors versus postsynaptic receptors,[8] the latter of which overcomes the former to increase postsynaptic dopaminergic signaling only with high doses.

See also

References

  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^